Do Payers Use Real-World Evidence to Guide Their Coverage and Reimbursement Decisions?
Payers infrequently used real-world evidence (RWE), or information on how treatments work in the real world, to guide their medication coverage and reimbursement decisions, according to new research published in the Journal of Managed Care & Specialty Pharmacy.
NPC Submits Comments to FDA on Exchange of Clinical and Economic Information
In comments submitted to the FDA, NPC outlined ways to improve how the exchange of clinical and economic information between biopharmaceutical manufacturers, payers, and population-health decision makers is regulated.
Including the Patient’s Perspective in Valuing Treatments for Arthritis
NPC President Dan Leonard sat down for a Q&A session with Sandie Preiss of the Arthritis Foundation to discuss how the value of treatments for arthritis is being assessed for the more than 50 million adults and approximately 300,000 children in the U.S. with some form of physician-diagnosed arthritis.